The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Gene to Block TNF Linked to Multiple Sclerosis but not Rheumatoid Arthritis

Gene to Block TNF Linked to Multiple Sclerosis but not Rheumatoid Arthritis

January 16, 2013 • By Kurt Ullman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Research from the United Kingdom indicates that a single nucleotide polymorphism (SNP) in the TNFRSF1A gene encoding the receptor for tumor necrosis factor (TNF) 1 is associated with multiple sclerosis (MS) but not rheumatoid arthritis (RA) or other autoimmune conditions.1 The SNP directs expression of a novel, soluble form of TNFR1 that can block TNF function.

You Might Also Like
  • TNF-α Impairs Regulatory T Cells in Patients with Rheumatoid Arthritis
  • Scientists Pinpoint Three HLA Proteins Linked to Seropositive Rheumatoid Arthritis
  • Study Shows Rheumatoid Arthritis Linked to Atrial Fibrillation
Also By This Author
  • Familial Patterns in Childhood- & Adult-Onset SLE

“The discrepancy in the efficacy of TNF-blocking drugs between MS and other autoimmune conditions, including RA, has remained a puzzle for over 10 years,” says Calliope A. Dendrou, PhD, a postdoctoral researcher in the Fugger laboratory of Weatherall Institute of Molecular Medicine at the University of Oxford. “Our work demonstrates that unlike other conditions, TNF blocking is a generic MS risk factor. Thus, a prior knowledge of the MS association of rs1800693 and of the functional effects it confers could have helped to predict the poor outcome of TNF blocking drugs in MS.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

rs18000693 Appears to be Culprit

MS-related genome-wide association reports have shown that rs18000693 is the most associated SNP in the region (odds ratio for risk allele=1.12, (1.11–1.14); P = 4.1 x 10-14). Statistical imputation found no other variant that could better explain this MS association within the region.

Dr. Dendrou and colleagues next looked at individuals carrying the MS risk allele at this SNP, finding significant increases in splicing out of exon 6 from TNFR1 transcripts. Furthermore, they also found that this novel splice variant translated into protein in primary human cells.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers functionally characterized the risk-associated protein (Δ6-TNFR1) encoded by this splice variant. Lastly, they demonstrated the soluble Δ6-TNFR1 is capable of binding and neutralizing TNF.

“Our main finding is that an MS genetic risk variant located in the TNFRSF1A gene directs the production of a soluble isoform of TNFR1 that can bind to and block TNF,” says Dr. Dendrou. “This risk effect mirrors the clinical experience with TNF blockers, whereby these drugs, whose properties are analogous (although greater in magnitude) to those of Δ6-TNFR1, have been found to promote or exacerbate the disease.”

Medically Informative

Given that the majority of MS-associated variants have only modest effects on disease risk, the clinical value of finding functional consequences of any genetic change has been a topic of debate. The group’s work shows follow-up investigations in this area can be medically informative.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“The analysis of disease-associated genetic regions provides a unique opportunity to revolutionize our understanding of the diseases such as RA and MS using genetic insights alongside functional studies so as to achieve better healthcare for patients,” she notes. “Our proof-of-principle study shows that the functional follow-up of common disease-associated genetic variants—despite their typically small individual effects on disease risk—can be clinically meaningful and will therefore constitute an active line of investigation in the autoimmune disease field that may change our understanding of these conditions, and thus the way we treat them.”

Pages: 1 2 | Single Page

Filed Under: Safety Tagged With: Multiple Sclerosis, Rheumatoid arthritis, TNF

You Might Also Like:
  • TNF-α Impairs Regulatory T Cells in Patients with Rheumatoid Arthritis
  • Scientists Pinpoint Three HLA Proteins Linked to Seropositive Rheumatoid Arthritis
  • Study Shows Rheumatoid Arthritis Linked to Atrial Fibrillation
  • TNF Inhibitors May Not Be Linked to Cancer Risk in Kids

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.